HER2-Negative Breast Cancer Global Market Report 2025
상품코드:1826937
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
HER2 음성 유방암 시장 규모는 최근 몇 년 동안 강력하게 성장하고 있습니다. 2024년 162억 9,000만 달러에서 2025년에는 175억 7,000만 달러에 달하고, CAGR 7.8%를 나타낼 전망입니다. 역사적인 기간의 성장은 유방암 환자 증가, 유방암에 대한 의식 증가, 헬스케어에의 지출 증가, 고령화, 의료 인프라의 확대에 기인하고 있습니다.
HER2 음성 유방암 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 7.7%를 나타내 236억 7,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 알코올 소비 증가, 건강에 해로운 라이프 스타일 채용 증가, 비만 유병률 증가, 담배 소비 증가, 효과적인 치료 솔루션에 대한 필요성 증가로 인한 것으로 예측됩니다. 예측기간의 주요 동향으로는 진단기술의 혁신, 표적요법의 통합, 면역요법의 통합, FDA 승인, 기술의 진보 등을 들 수 있습니다.
HER2 음성 유방암은 유방암의 일종으로 암세포가 종양의 성장을 가속하는 HER2 단백질을 과발현하지 않는 유형입니다. 이 유형의 암은 일반적으로 HER2 양성 유방암보다 증식이 느리고 표적 요법과 화학 요법을 사용하여 치료됩니다.
HER2 음성 유방암의 주요 치료법에는 항암제 치료, 호르몬 요법, 표적 요법, 면역요법이 있습니다. 항암제 치료에서는 체내에서 급속하게 분열하는 세포를 표적으로 하여 강력한 약제를 이용하여 암세포를 파괴하거나 증식을 억제합니다. 치료는 조기, 국소 진행기, 전이기 등 다양한 단계에서 이루어지고, 병원 약국, 소매 약국, 온라인 약국을 통해 유통하고 있습니다.
2025년 봄 미국 관세의 급상승과 이에 따른 무역 마찰은 의료 분야, 특히 필수적인 의료기기, 진단 장비 및 의약품 공급에 큰 영향을 미쳤습니다. 병원과 건강 관리 제공업체는 수입되는 수술 기구, 영상 진단 시스템, 주사기 및 카테터와 같은 소모품의 비용 상승에 시달리고 있으며, 그 대부분은 국내 대체품이 제한되어 있습니다. 이러한 비용 상승이 의료 예산을 압박하기 때문에 일부 의료기관은 장비 업그레이드를 늦추거나 비용 증가를 환자에게 전가하고 있습니다. 게다가 원료와 부품에 대한 관세는 중요한 의약품과 의료기기의 제조에 지장을 주고 공급망의 지연으로 이어지고 있습니다. 이에 비해 업계는 다양한 조달 전략을 채택하고 가능한 한 현지 생산을 확대하고 중요한 의료 제품의 관세 면제를 수행하고 있습니다.
이 조사 보고서는 HER2 음성 유방암 산업 세계 시장 규모, 지역 점유율, HER2 음성 유방암 시장 점유율을 가진 경쟁 기업, 상세한 HER2 음성 유방암 시장 부문, 시장 동향과 비즈니스 기회 등 HER2 음성 유방암 시장 통계를 게시하고 HER2 음성 유방암 업계에서 성공하기 위해 필요한 데이터를 제공하는 The Business 이 HER2 음성 유방암 시장 조사 보고서는 업계의 현재 및 미래 시나리오를 자세히 분석하고 필요한 모든 것을 완벽한 관점에서 제공합니다.
향후 5년간의 성장률 7.7%라고 하는 예측은 전회 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세장벽은 영국이나 싱가포르에서 조달되는 CDK4/6 억제제(파르보시클리브 등)나 PARP 억제제의 비용을 상승시킴으로써 미국 시장을 억제하고 전이성 질환의 제어를 늦추고 종양 약국의 비용을 상승시킬 것으로 예측됩니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.
유방암 이환율 증가는 HER2 음성 유방암 시장 성장을 가속할 것으로 예측됩니다. 유방암은 유방 조직에서 비정상적인 세포의 통제 불가능한 증식을 특징으로 하는 질환으로, 일반적으로는 유관이나 소엽에 발생합니다. 유방암 환자 수 증가에는 의식 증가와 조기 빈번한 발견으로 이어지는 스크리닝 기술의 진보 등 몇 가지 요인이 기여하고 있습니다. HER2 음성 유방암 연구는 명확한 종양 생물학을 이해하고 치료 성적을 개선하는 표적 요법을 개발하는데 매우 중요합니다. 예를 들어, 2024년 6월 미국 정부기관인 질병대책예방센터는 2021년 미국에서 새롭게 27만 2,454명의 여성이 유방암으로 진단되었고, 2022년에는 4만 2,211명이 사망했다고 보고했습니다. 이 유병률 증가는 효과적인 HER2 음성 유방암 치료에 대한 수요 증가를 뒷받침하고 있습니다.
HER2 음성 유방암 시장 주요 기업은 새로운 치료를 도입하고 제품 라인업을 확대하고 시장에서의 존재감을 강화하기 위해 규제 당국의 승인을 적극 추구하고 있습니다. 규제 당국의 승인은 의약품 및 치료가 상업화 전에 안전성, 효능 및 품질 기준을 충족하는지 확인하기 위해 정부 기관이 제공하는 공식 인가입니다. 예를 들어, 2024년 10월, 미국의 생명공학기업인 제넨텍사는 PIK3CA 변이를 가진 진행성 호르몬 수용체 양성(HR) HER2 음성 유방암의 표적 치료제로서 이토베비(이나보리시브)의 FDA 승인을 취득했습니다. 이번 승인을 통해 이토베비는 파르보시클리브 및 풀베스트란트와의 병용 투여가 가능해 표준치료에 비해 무증악 생존기간을 유의하게 연장합니다. 이번 승인된 요법은 대체 치료가 제한된 환자에게 매우 중요한 치료 옵션을 제공하며, 이 치료의 혜택을 받을 가능성이 가장 높은 환자를 식별하는 바이오마커 검사의 중요성을 돋보이게 합니다.
2024년 6월 미국의 임상 단계에 있는 Precision Medicine 기업인 릴레이 세라퓨틱스사는 화이자사와 제휴해 PI3Ka 변이, HR, HER2 전이성 유방암 환자를 대상으로 화이자사의 임상시험 중 선택적 CDK4 억제제인 아티리모시클리브와 RLY-2608 및 풀베스트란트의 병용요법을 평가했습니다. 이 공동 연구는 두 약물의 다른 특성을 활용하고 지금까지 비 선택적 약물의 효능을 제한해 온 표적 외독성을 최소화하는 것을 목표로 합니다. 미국에 본사를 둔 제약 및 바이오테크놀러지 기업인 화이자사는 HER2 음성 유방암의 혁신적 치료법 개발에 중요한 역할을 계속하고 있습니다.
HER2 음성 유방암 시장에는 방사선 요법, 유전 검사, 유방 조영술, 상담 및 심리적 지원과 같은 서비스를 제공하는 기업이 얻는 수익이 포함됩니다. 시장 가치에는 서비스 제공업체가 판매하거나 서비스 제공에 포함된 관련 상품의 가치도 포함됩니다. 사업자간에 거래되거나 최종 소비자에게 판매되는 재화 및 서비스만 포함됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 HER2 음성 유방암 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 HER2 음성 유방암 시장 : 성장률 분석
세계의 HER2 음성 유방암 시장 실적 : 규모와 성장(2019-2024년)
세계의 HER2 음성 유방암 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 HER2 음성 유방암 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 HER2 음성 유방암 시장 : 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
항암제 치료
호르몬 치료
표적 치료
면역 치료
세계의 HER2 음성 유방암 시장 : 암 단계별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
조기 단계
국소 진행 단계
전이 단계
세계의 HER2 음성 유방암 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
세계의 HER2 음성 유방암 시장 : 항암제 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
안트라사이클린
탁산계
백금 기반 항암제 치료
알킬화제
항대사물질
세계의 HER2 음성 유방암 시장 : 호르몬 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
선택적 에스트로겐 수용체 조절제(SERM)
아로마타제 억제제
선택적 에스트로겐 수용체 분해제(SERD)
세계의 HER2 음성 유방암 시장 : 표적 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
CDK4/6 억제제
PI3K 억제제
PARP 억제제
세계의 HER2 음성 유방암 시장 : 면역 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
면역 체크포인트 억제제
종양 침윤 림프구(TIL) 치료
제7장 지역별/국가별 분석
세계의 HER2 음성 유방암 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 HER2 음성 유방암 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
HER2 음성 유방암 시장 : 경쟁 구도
HER2 음성 유방암 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Sanofi SA
AstraZeneca PLC
Novartis International AG
Eli Lilly and Company
Amgen Inc.
Daiichi Sankyo Company Limited
Jiangsu Hansoh Pharmaceutical Co. Ltd.
BeiGene Ltd.
Chipscreen Biosciences Ltd.
F. Hoffmann-La Roche Ltd
PharmAbcine Inc.
Adagene Inc.
H3 Biomedicine Inc.
Radius Health Inc.
Zenith Epigenetics Ltd.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
HER2 음성 유방암 시장(2029년) : 새로운 기회를 제공하는 국가
HER2 음성 유방암 시장(2029년) : 새로운 기회를 제공하는 부문
HER2 음성 유방암 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
HER2-negative breast cancer is a type of breast cancer in which the cancer cells do not overexpress the HER2 protein, which is responsible for promoting tumor growth. This form of cancer generally grows more slowly than HER2-positive breast cancer and is treated using targeted therapies and chemotherapy.
The primary treatment options for HER2-negative breast cancer include chemotherapy, hormone therapy, targeted therapy, and immunotherapy. Chemotherapy involves the use of powerful drugs to destroy or inhibit the growth of cancer cells by targeting rapidly dividing cells in the body. Treatment is administered at various stages, including the early stage, locally advanced stage, and metastatic stage, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The HER2-negative breast cancer market research report is one of a series of new reports from The Business Research Company that provides HER2-negative breast cancer market statistics, including HER2-negative breast cancer industry global market size, regional shares, competitors with HER2-negative breast cancer market share, detailed HER2-negative breast cancer market segments, market trends and opportunities, and any further data you may need to thrive in the HER2-negative breast cancer industry. This HER2-negative breast cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The her2-negative breast cancer market size has grown strongly in recent years. It will grow from $16.29 billion in 2024 to $17.57 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to the rise in breast cancer cases, increased awareness about breast cancer, increased spending on healthcare, an aging population, and expanding healthcare infrastructures.
The her2-negative breast cancer market size is expected to see strong growth in the next few years. It will grow to $23.67 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing consumption of alcohol, increasing adoption of unhealthy lifestyles, increasing prevalence of obesity, increasing consumption of tobacco, and increasing need for effective treatment solutions. Major trends in the forecast period include innovations in diagnostic technologies, integration of targeted therapies, integration of immunotherapies, FDA approvals, and technological advancements.
The forecast of 7.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. market by increasing the cost of CDK4/6 inhibitors (e.g., palbociclib) and PARP inhibitors sourced from the UK and Singapore, thereby delaying metastatic disease control and elevating oncology pharmacy costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing incidence of breast cancer is expected to drive the growth of the HER2-negative breast cancer market. Breast cancer is a disease characterized by the uncontrolled growth of abnormal cells in the breast tissue, typically originating in the ducts or lobules. Several factors contribute to the rising number of breast cancer cases, including heightened awareness and advancements in screening technologies, which lead to earlier and more frequent detection. HER2-negative breast cancer research is critical in understanding distinct tumor biology and developing targeted therapies that improve treatment outcomes. For example, in June 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that in 2021, 272,454 new cases of breast cancer were diagnosed among females in the United States, with 42,211 deaths recorded in 2022. This growing prevalence underscores the increasing demand for effective HER2-negative breast cancer treatments.
Leading companies in the HER2-negative breast cancer market are actively pursuing regulatory approvals to introduce new treatments, expand their product offerings, and strengthen their market presence. Regulatory approvals represent official authorizations granted by government agencies, ensuring that drugs and treatments meet safety, efficacy, and quality standards before commercialization. For instance, in October 2024, Genentech Inc., a US-based biotechnology corporation, secured FDA approval for Itovebi (inavolisib) as a targeted treatment for advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This approval enables Itovebi to be administered in combination with palbociclib and fulvestrant, significantly enhancing progression-free survival compared to standard treatments. The newly approved regimen offers a crucial treatment option for patients with limited alternatives, highlighting the importance of biomarker testing in identifying those most likely to benefit from the therapy.
In June 2024, Relay Therapeutics Inc., a US-based clinical-stage precision medicine company, partnered with Pfizer Inc. to evaluate the combination of atirimociclib, Pfizer's investigational selective CDK4 inhibitor, with RLY-2608 and fulvestrant in patients with PI3Ka-mutated, HR+, HER2- metastatic breast cancer. This collaboration seeks to leverage the distinct properties of both drugs to minimize off-target toxicity, which has historically limited the effectiveness of non-selective agents. Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, continues to play a key role in the development of innovative treatments for HER2-negative breast cancer.
Major players in the her2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.
North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in HER2-negative breast cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the HER2-negative breast cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The HER2-negative breast cancer market includes revenues earned by entities by providing services such as radiation therapy, genetic testing, mammography, and counseling and psychological support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
HER2-Negative Breast Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on her2-negative breast cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for her2-negative breast cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The her2-negative breast cancer market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. HER2-Negative Breast Cancer Market Characteristics
3. HER2-Negative Breast Cancer Market Trends And Strategies
4. HER2-Negative Breast Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global HER2-Negative Breast Cancer Growth Analysis And Strategic Analysis Framework
5.1. Global HER2-Negative Breast Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global HER2-Negative Breast Cancer Market Growth Rate Analysis
5.4. Global HER2-Negative Breast Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global HER2-Negative Breast Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global HER2-Negative Breast Cancer Total Addressable Market (TAM)
6. HER2-Negative Breast Cancer Market Segmentation
6.1. Global HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Hormone Therapy
Targeted Therapy
Immunotherapy
6.2. Global HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Early Stage
Locally Advanced Stage
Metastatic Stage
6.3. Global HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.4. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anthracyclines
Taxanes
Platinum-Based Chemotherapy
Alkylating Agents
Antimetabolites
6.5. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Selective Estrogen Receptor Modulators (SERMs)
Aromatase Inhibitors
Selective Estrogen Receptor Degraders (SERDs)
6.6. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
CDK4/6 Inhibitors
PI3K Inhibitors
PARP Inhibitors
6.7. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immune Checkpoint Inhibitors
Tumor-Infiltrating Lymphocyte (TIL) Therapy
7. HER2-Negative Breast Cancer Market Regional And Country Analysis
7.1. Global HER2-Negative Breast Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global HER2-Negative Breast Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific HER2-Negative Breast Cancer Market
8.1. Asia-Pacific HER2-Negative Breast Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China HER2-Negative Breast Cancer Market
9.1. China HER2-Negative Breast Cancer Market Overview
9.2. China HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India HER2-Negative Breast Cancer Market
10.1. India HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan HER2-Negative Breast Cancer Market
11.1. Japan HER2-Negative Breast Cancer Market Overview
11.2. Japan HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia HER2-Negative Breast Cancer Market
12.1. Australia HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia HER2-Negative Breast Cancer Market
13.1. Indonesia HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea HER2-Negative Breast Cancer Market
14.1. South Korea HER2-Negative Breast Cancer Market Overview
14.2. South Korea HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe HER2-Negative Breast Cancer Market
15.1. Western Europe HER2-Negative Breast Cancer Market Overview
15.2. Western Europe HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK HER2-Negative Breast Cancer Market
16.1. UK HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany HER2-Negative Breast Cancer Market
17.1. Germany HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France HER2-Negative Breast Cancer Market
18.1. France HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy HER2-Negative Breast Cancer Market
19.1. Italy HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain HER2-Negative Breast Cancer Market
20.1. Spain HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe HER2-Negative Breast Cancer Market
21.1. Eastern Europe HER2-Negative Breast Cancer Market Overview
21.2. Eastern Europe HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia HER2-Negative Breast Cancer Market
22.1. Russia HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America HER2-Negative Breast Cancer Market
23.1. North America HER2-Negative Breast Cancer Market Overview
23.2. North America HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA HER2-Negative Breast Cancer Market
24.1. USA HER2-Negative Breast Cancer Market Overview
24.2. USA HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada HER2-Negative Breast Cancer Market
25.1. Canada HER2-Negative Breast Cancer Market Overview
25.2. Canada HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America HER2-Negative Breast Cancer Market
26.1. South America HER2-Negative Breast Cancer Market Overview
26.2. South America HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil HER2-Negative Breast Cancer Market
27.1. Brazil HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East HER2-Negative Breast Cancer Market
28.1. Middle East HER2-Negative Breast Cancer Market Overview
28.2. Middle East HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa HER2-Negative Breast Cancer Market
29.1. Africa HER2-Negative Breast Cancer Market Overview
29.2. Africa HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. HER2-Negative Breast Cancer Market Competitive Landscape And Company Profiles
30.1. HER2-Negative Breast Cancer Market Competitive Landscape
30.2. HER2-Negative Breast Cancer Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
31. HER2-Negative Breast Cancer Market Other Major And Innovative Companies
31.1. Sanofi S.A.
31.2. AstraZeneca PLC
31.3. Novartis International AG
31.4. Eli Lilly and Company
31.5. Amgen Inc.
31.6. Daiichi Sankyo Company Limited
31.7. Jiangsu Hansoh Pharmaceutical Co. Ltd.
31.8. BeiGene Ltd.
31.9. Chipscreen Biosciences Ltd.
31.10. F. Hoffmann-La Roche Ltd
31.11. PharmAbcine Inc.
31.12. Adagene Inc.
31.13. H3 Biomedicine Inc.
31.14. Radius Health Inc.
31.15. Zenith Epigenetics Ltd.
32. Global HER2-Negative Breast Cancer Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The HER2-Negative Breast Cancer Market
34. Recent Developments In The HER2-Negative Breast Cancer Market
35. HER2-Negative Breast Cancer Market High Potential Countries, Segments and Strategies
35.1 HER2-Negative Breast Cancer Market In 2029 - Countries Offering Most New Opportunities
35.2 HER2-Negative Breast Cancer Market In 2029 - Segments Offering Most New Opportunities
35.3 HER2-Negative Breast Cancer Market In 2029 - Growth Strategies
